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Insulin and IGF seem to be important players in modulating brain aging. Neurons share more similarities with islet cells than any
other human cell type. Insulin and insulin receptors are diﬀusely found in the brain, especially so in the hippocampus. Caloric
restriction decreases insulin resistance, and it is the only proven mechanism to expand lifespan. Conversely, insulin resistance
increaseswithage,obesity,andsedentarism,allofwhichhavebeenshowntoberiskfactorsforlate-onsetAlzheimer’sdisease(AD).
Hyperphagia and obesity potentiate the production of oxidative reactive species (ROS), and chronic hyperglycemia accelerates the
formation of advanced glucose end products (AGEs) in (pre)diabetes—both mechanisms favoring a neurodegenerative milieu.
Prolongedhighcerebral insulinconcentrationscausemicrovascularendotheliumproliferation,chronichypoperfusion,andenergy
deﬁcit, triggering β-amyloid oligomerization and tau hyperphosphorylation. Insulin-degrading enzyme (IDE) seems to be the
main mechanism in clearing β-amyloid from the brain. Hyperinsulinemic states may deviate IDE utilization towards insulin
processing, decreasing β-amyloid degradation.
1.Introduction
Aging can be deﬁned as a process that invariably causes
a decline in the abilities of the individuals to face environ-
mentalstressors, leadingtoa dysfunction in homeostasis and
an increased incidence of chronic degenerative diseases [1].
Cognitive decline, which is an important aspect of aging,
is a leading cause of morbidity and mortality among the
elderly, since it greatly impairs their activities of daily living
and quality of life [2].
Some patterns of neurodegeneration involved in cog-
nitive impairment are highly preserved phylogenetically in
mammals—such as reduced synaptic activity in neurons,
alterations in glial metabolism, and accumulation of speciﬁc
metabolic products [3].
In this chapter we will review the relationships between
some disorders of metabolism related to insulin dysfunction
and cognitive declineand the importance of these alterations
to the neurodegenerative process in aging-related disorders,
particularly Alzheimer’s disease.
2.InteractionsbetweenAging and
Insulin Regulation
The ultimate cause of senescence remains unknown. How-
ever, Some speciﬁc mechanisms possess major roles in reg-
ulating the aging process [4, 5]. Presently, reconciliation
between the two main theories of aging would be the pro-
posal that the cumulative eﬀects of the Reactive Oxygen
Species (ROS) and Advanced Glycation End products (AGE)
leads to aging. In another words, aging would be the conse-
quenceofa biologicalprocess equivalentto combustion,that
is, the burning of calories by inhaled oxygen.
In fact, dietary restriction is the only well-established
mechanism proved to expand life span, as demonstrated in
animal models [6, 7]. This could be related to a lower mito-
chondrial respiratory rate, which determines lower produc-
tion of ROS and, as a possible consequence, longer life
span in animals. These compounds, which originated from
cellular respiratory process, could damage DNA, proteins,2 ISRN Neurology
and structural lipids. Human body is constantly generating
these molecules as natural products from cell function.
To counteract the deleterious eﬀects of ROS, there are
agreatnumberofenzymatic mechanisms thatscavengethese
compounds—the antioxidants. It is speculated that, with
aging, there would be a dysfunction in mitochondrial activ-
ity, leading to an increased production of ROS, accompanied
by a decrease in the action of the antioxidants. Through this
mechanism, there would be an accumulation of damaged
cellular structures and, ﬁnally, cell death [8].
The other important mechanism hypothesized to have
a role in aging is the accumulation of AGEs. This process
takes place when proteins are exposed to chronic elevated
high levels of glucose. A nonenzymatic reaction occurs and
these compounds accumulate in the body, leading to toxic
eﬀects. In fact, there are an emerging amount of evidence
pointing to the link between this process with normal aging
and dementia (particularly Alzheimer’s disease), even in the
absence of diabetes [9, 10].
3. Insulin and the Brain
Insulin is the most important body response to storage
energyafterameal.Itisapeptidehormonesecretedbyβcells
in pancreatic islets, and its serum concentration increases
in a direct proportion to the glucose concentration. Other
substrates, like amino acids and ketone bodies, can also
stimulate its secretion. Moreover, insulin secretion is under
neuronal control, and the anticipation of a meal can activate
the parasympathetic pathway and stimulate insulin secretion
without the presence of glucose. Insulin facilitated tissue
uptake of glucose from blood to immediate oxidation or to
storage. Adiposity is another factor that inﬂuences insulin
secretion and the expression of peripheral insulin receptors
[11].
For a long time, the brain was thought to be an insulin-
independent organ [12]. However, insulin receptors are ex-
pressed throughout the brain in neurons and glial cells,
suggesting a role for this hormone in cerebral function
[13–15]. The concentration of these receptors is higher in
particularareas, likehypothalamusand hippocampus,where
it seems to act controlling feeding and body weight [16–18].
Moreover, neurons and pancreatic β cells share some simi-
latities, and it is believed that they have evolved from a com-
mon ancestral neuron that produced insulin [19]. Insulin
can reach central nervous system through cincumventricular
areas without blood-brain barrier (BBB) and by the action
of a speciﬁc insulin receptor that transports insulin into the
brain through the BBB [20, 21]. This transport mechanism
has a limited action, being saturated with high substrate
concentration. There is evidence that high insulin levels in
bloodstream results in hyperinsulinemia in cerebrospinal
ﬂuid [22]. However, more recently, data suggest that chronic
hyperinsulinemia reduced its blood-brain transport [23].
Insulin is vital for proper brain tissue function and it
seems to have a general neurotrophic eﬀect. In fact, there
is a large body of evidence that this hormone has an
importantroleasaneurotrophicfactorinneuriteoutgrowth.
As a possible consequence of this primary mechanism,
insulin can inﬂuence synaptic plasticity, learning, and mem-
ory processes. Insulin also regulates the internalization of
neurotransmitters at several receptor sites [24].
The signal transduction after the binding of insulin in
its surface receptor (insulin receptor—Irc) is complex, with
the activation of a great amount of second messengers. The
Irc receptor, when activated by insulin, has an intrinsic
tyrosine kinase activity, forming phosphotyrosine residues
that are dock sites to adaptor proteins, like insulin receptor
substrates 1 and 2 (IRS1, IRS2). These molecules activate
other proteins, initiating several signaling cascades. One of
them isthe lipidkinase phosphatidylinositol3-kinase (PIK3),
which is responsible for almost all of the metabolic actions
of insulin. PIK3 acts in the membrane phospholipid PIP2
(phosphatidylinositol 4,5 biphosphate) turning it into PIP3
(phosphatidylinositol 3,4,5 triphosphate). PIP3 recruits PKB
(protein kinase B, also called Akt), which targets GSK3
(glycogen synthase kinase 3). Phosphorylation of GSK3 by
PKB causes its inactivation, reducing the phosphorylation
of glycogen synthase (GS). This decreased phosphorylation
leads to a more active GS metabolite, which increases the
conversion of glucose-6-phosphate to glycogen. Besides this
actions related to glucose metabolism, insulin receptor acti-
vation also acts through the MAP kinase pathway aﬀecting
general gene expression [25].
Insulin alsoparticipatesin many othercomplexreactions
in the brain through diﬀerent mechanisms which are less
intrinsically related to aging and, therefore, stands outside
the scope of this review (see [24]f o rar e v i e w ) .
4.Metabolic DisordersandCognitiveDecline
In the last decade there has been a rapid increase in pub-
lications focused on the relationships between metabolic
disorders, such as diabetes, obesity and metabolic syndrome,
and a higher risk for cognitive decline and dementia
(Figure 1).Theﬁnding thatmetabolicdisordersmayincrease
the risk of dementia has raised many new questions, whose
answers may have critical implications, such as the way we
d e ﬁ n ea n dc l a s s i f yt h ed e m e n t i a s[ 26].
The peripheral insulin resistance syndrome occurs when
tissues become less responsive to the eﬀects of insulin,
aﬀecting itsactions on cellularglucoseuptakeand regulation
of blood glucose levels. It is typically accompanied by
compensatory hyperinsulinemia in the periphery, which has
independent toxic deleterious eﬀects upon cells. Insulin
resistance is thought to be the underlying cause of metabolic
syndrome and type-2 diabetes (DM.2), having, in many
cases, an important role also in the development of vascular
disorders such as hypertension and cardiovascular disease
[28].
DM.2 can be considered as a pole of the insulin
resistance syndrome spectrum and, just like dementia, is also
a common age-related chronic disorder. About 250 million
people around the world suﬀer from this disease, and 6
million new cases are reported each year [29]. Its prevalence
increases with age: from 12% inpeople aged 65 to 70 years toISRN Neurology 3
↓ Cognition
Chronic hyperglycemia
- Protein glycation and other advanced
glycation end products (AGE)
- Generation of reactive oxygen species (ROS)
- Increased inﬂammation
- Altered myelin formation
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Figure 1: Key components of the Metabolic Syndrome (Met.S), and their possible mechanisms leading to neurodegeneration and cognitive
decline. All Met.S components may contribute to cause cerebral small-vessel disease, neurodegeneration, and cognitive decline. However,
obesity-related insulinresistance,causinghyperinsulinism,is thoughtto be theunifyingpathophysiologicalmechanismforthedevelopment
of Met.S. Aging is associated with increased insulin resistance and Met.S prevalence, and may also aggravate the severity/control of most
components of this syndrome. Adapted, with authorization,from Roriz-Filho et al. 2009 [27].
15% in people over age 80 [30]. This will represent an even
greater burden in the near future, since the population older
than 60 is expected to increase by 50% in the next 20 years
(TheUSCensusBureau).Diabetesisamultisystemicdisorder
which could damage any organ in the body. Pathologic
changes can occur in both large and small vessels, cranial
and peripheral nerves, skin, and eyes. These changes have
been traditionally associated with renal failure, vision loss,
autonomic and peripheral neuropathy, peripheral vascular
disease, myocardial infarction, and cerebrovascular disease
[31].
The associations between diabetes and stroke, as well
as those between diabetes and vascular dementia (VD), are
already well established, being of obvious association [32–
34]. Nevertheless, the connections between diabetes and
other forms of cognitive decline seem to involve more subtle
and complex mechanisms.
In the last years, the line border separating Alzheimer
Disease (AD) from VD has become blurred [35]. VD is
a heterogeneous disorder which can have its pathological
presentation ranging from multiple macroinfarcts to small-
vessel ischemic disease or microvascular injury. Biswanger
disease is a subtype of vascular dementia caused by several
brain microinfarcts and/or a by a chronic oligaemic state
leading to white matter degeneration [36]. Neuropatholog-
ical markers of vascular injury not only often coexist with
AD-related amyloid burden, but also seems to correlate well
with the degree of this burden. In fact, amyloid burden
may conceivably be promoted by microvascular injury.
A chronic oligaemic brain condition may predispose to the
activation of the amyloidogenic pathway, increasing A-beta
oligomerization and deposition [37]. Besides, chronic brain
hypoperfusion also seems to stimulate tau hyperphospho-
rylation. BBB dysfunction may aﬀect β-amyloid transport
between the brain and the periphery, thereby contributing
to parenchymal and neurovascular amyloid deposition [37].
Conversely, amyloid may cause vascular injury, as when
amyloid-induced inﬂammatory damage to the endothelium
(amyloid angiopathy) [26, 38].
A prospective population-based study with 6,370 elderly
subjects found that the risk for both overall dementia and
Alzheimer’s disease was increased by diabetes [39], with
an even higher risk among people treated with insulin
(of presumably more severe disease). Other authors have
unequivocally conﬁrmed this association in diﬀerent popu-
lations [40–44]. Several studies have demonstrated increased
risk of cognitive decline among subjects with Met.S and/or
prediabetes [27, 45–48]. Met.S is deﬁned (depending on
the clinical criteria utilized) as a constellation of cardio-
vascular risk factors such as visceral obesity, dyslipidemia,
hypertension, and hyperglycemia [49].Prediabetes isdeﬁned
as a syndrome presenting with impaired fasting glucose
and/or impaired glucose tolerance in which the risk for
developing type-2 DM is increased. All the three syndromes
above described have insulin resistance and consequent
hyperinsulinism as their central pathophysiological feature.
The mechanisms by which Met.S components may lead to
c o g n i t i v ed e c l i n ea r ed e p i c t e di nFigure 1.
Hyperglycemia is a major feature of diabetes [50]. In
rodents it is associated with impairment in several cognitive4 ISRN Neurology
domains. Modiﬁcations in brain tissue structure are ulti-
mately attributed to increased activation of polyol and hex-
osamine pathways, disruption of intracellular second mes-
senger mechanisms, disequilibrium between the generation
and scavenging of ROS, and to the accumulation of AGEs,
causingimportantfunctionalandstructuralmodiﬁcationsin
cell proteins [51].
High fasting plasma insulin concentration is a condition
thatprecedeshyperglycemia by many years, predicting DM.2
[52]. This situation seems to be caused by peripheral insulin
resistance, which is associated with increased risk of cog-
nitive decline and dementia [45, 53]. Insulin resistance is
a condition where the hormone has diﬃculty in exerting its
role, due to receptor dysfunction or alterations in second
messenger transduction [28]. Some evidences point towards
a positive relationship between peripheral hyperinsulinism
and cognitive decline, even in the absence of diabetes. In
two studies, lower Mini-Mental State Examination (MMSE)
scores were associated with higher insulin serum levels,
even when controlled for cardiovascular disease and after
excluding diabetic subjects [53, 54]. Possible mechanisms in
explaining the role of hyperinsulinism in neurodegeneration
are (1) sensibilization of neurons to toxins and other insults
in the presence of high insulin concentration levels; (2)
decrease transportation of insulin into the brain; (3) tau
hyperphosphorylation caused by brain insulin resistance; (4)
increase in β-Amyloid secretion and decrease in its clearance
due to competition between Insulin and β-Amyloid for
the Insulin-Degrading Enzyme (IDE); (5) brain localized
hypoglycemic states caused by insulin resistance.
It was demonstrated that insulin administration to
elderly subjectselevatescerebrospinal β-Amyloid at 120min,
and this phenomena was correlated with poor cognitive
performance [55]. Despite that, it is not yet clear if chronic
high serum insulin levels are associated with increased cere-
brospinal insulin concentrations. In fact, there are evidences
pointing to the contrary [56, 57]. Cerebrospinal ﬂuid (CSF)
of people with Alzheimer’s disease has lower concentrations
ofinsulin, as compared with controls[58]. This suggests that
its relative deﬁciency, instead of its excess, could be in part
responsible for neurodegeneration.
Acutely,high peripheral insulin levels are associated with
increased concentrations of insulin in cerebrospinal ﬂuid
[55]. With the chronicity of the hyperinsulinemia, there is
a downregulation in transportation mechanisms, which may
explain why Alzheimer’s patients have lower concentrations
of insulin in the cerebrospinal ﬂuid [56, 58]. Furthermore, it
is possible that peripheral insulin resistance could decrease
insulin transportation into the brain. Brain capillaries of
insulin-resistant obese rats have reduced insulin aﬃnity and
decreased insulin levels in the hypothalamus [20, 59].
This apparent insulin paradox was consistently demon-
strated in many other studies with diﬀerent methodological
approaches. At instance, acuteadministration ofintravenous
insulin in humans and intraventricular insulin in rats
improved memory functions [60, 61]. Recently, it was
described that intranasal insulin could properly reach the
central nervous system, enhancing memory task perfor-
mance in humans [62]. In addition, rats trained in tasks
involving spatial memory showed increased insulin receptor
expression and function [63]. In accordance with previous
knowledge that insulin has neurotrophic properties, these
data provide evidence that high insulin concentrations
improves cognition, at least in acute scenarios. The most
reasonable explanation for this apparent paradoxical eﬀect
might be attributed to the diﬀerences between acute and
chronic responses to insulin. Acutely, increases in brain
insulin levels have neurotrophic eﬀects, while high chronic
insulin levels may have a deleterious eﬀect. In fact, there is
evidence for an autoregulatory homeostatic brain mecha-
nism which tries to decrease this state of perpetuated high
brain insulin concentration.
5.Insulin Neurotrophicversus
NeurotoxicEffects
Insulin might have an eﬀect in sensitization of neurons to
excitoxicity. In a rat neuron culture model, it was demon-
strated that insulin increases lethal cytotoxic eﬀects of exci-
t a t o r ya m i n oa c i d s ,s u c ha sg l u t a m a t e .T h i se ﬀect was
not observed with other growth factors and seems to be
speciﬁc for insulin. Moreover, the eﬀect was retained with
diﬀerent types of excitatory amino acids, suggesting that
this phenomenon occur at the intracellular level, rather than
in membrane receptor level. Although it has never been
demonstrated either in vivo, these data reasonably suggest
that insulin is a potentially toxic molecule when at very high
neuronal concentrations [64, 65].
Despite of this possible neurotoxic eﬀect of insulin in
animal models, itis well establishedthatthis hormonehas an
important role as a neuronal survival factor [66, 67]. In fact,
insulin seems to protect against the toxic eﬀects of AMPA,
oxygen/glucose deprivation and to prevent apoptosis [68–
72].Patientswithinsulinresistance havelossofinsulinsignal
transduction. Losing the protective eﬀects of insulin, they
may be at increased risk for neurodegeneration.
6.Insulin andAlzheimer’s Disease
Several cognitive functions seems to be aﬀected by type-2
diabetes mellitus (Table 1). Obese and diabetic people, as
well as those with Met.S, are at increased risk of AD [39, 45].
An MRI study compared brains of demented patients with
and without diabetes, showing that DM.2 increase cortical
atrophy [73]. Older diabetic subjects had increased atrophy
of hippocampus, as compared with their paired controls
[74]. Thought neither sensible nor speciﬁc enough, hip-
pocampal atrophy is one of the earliest neuroradiological
signs of AD. Moreover, diﬀuse cortical atrophy is also more
severe among diabetic than nondiabetic Alzheimer’s patients
[29, 73].
6.1. Insulin and Tau Phosphorylation. Microtubule Associ-
ated Protein (MAP) Tau is the molecule responsible for the
stabilization of microtubules inside the axons. It determines
an eﬃcient and adequate axoplasmic ﬂow, maintaining neu-
ronal connections and turning signal transmission possibleISRN Neurology 5
Table 1: Summary of cognitive functions found to be aﬀected in
Type 2 Diabetes Mellitus (T2DM).
Cognitive functions T2DM
Verbal memory ↓
∗
Nonverbal memory ↓
∗
Attention ↓
Visuospatial performance —
Processing speed ↓
∗
Executive function ↓
∗
Psychomotor eﬃciency —
General intelligence —
Adaptedfromreference[27],withpermission.↓:decreased;—doesnotseem
to be aﬀected or evidence lacking. Note: domains marked by asterisks have
particularly strong supporting data (see [75, 76]).
[77–79]. One of the hallmarks of AD is the accumulation
of aggregates of hyperphosphorylated tau protein inside the
cells, named neuroﬁbrillary tangles [80]. The exact role
for this aggregation in the pathogenesis of AD remains
u n k n o w n ,b u ti ti sb e l i e v e dt h a ti tc o u l db ea t t r i b u t e dt o
an intrinsic neurotoxicity state and/or a deﬁciency in ax-
oplasmic transport. Others believe that this aggregate is
only a reactive protective response against toxic insults.
Interestingly, β-amiloid toxicity was not observed in the
neurons of tau knockoutmice, suggesting that the formation
of neuroﬁbrillary tangles is an essential step for neurodegen-
eration to occur [81].
It has been demonstrated, in both cell culture and in vivo
models, that insulin has a pivotal role in regulating tau func-
tion [82–85]. Tau could be phosphorylated at Ser202 residue
by extracellular regulated kinase (Erk) family and at Thr231
by glycogen synthase kinase 3 (GSK3). It has been demon-
strated in animal models that the rising levels of insulin lead
to an activation of Erk, resulting in tau phosphorylation
at Ser202, and in an increased number of neuroﬁbrillary
tangles [86]. Since there is already a strong body of evidence
supporting the relationship between hyperinsulinism and
cognitive decline, hyperphosphorylation of tau could be a
plausible implied mechanism for this relationship.
Tau is a substrate forcaspase activity, and the productsof
this reaction form molecules that could be phosphorylated
by GSK3 [87]. In turn, GSK3 is a constitutively active, pro-
line-directed serine/threoninek i n a s et h a tp l a y si m p o r t a n t
roles in a great variety of physiological processes. The
decreased activation of insulin receptor caused by insulin
resistance results in a decreased phosphorylation of GSK3,
turning it more active. The activated GSK3 phosphorylates
tau and tau-derived products at the Thr231 residue, which
ultimately accelerates the formation of neuroﬁbrillary tan-
gles [88].
The relationship between insulin resistance, hyperin-
sulinism, and tau hyperphosphorylation in the formation
of neuroﬁbrillary tangles is, therefore, supported by several
lines of evidence [89, 90].
6.2. Insulin and the β-Amyloid Cascade. Deposition of β-
amyloid plaques in the extracellular space is the other hall-
mark in the pathology of Alzheimer’s disease. These plaques
are formed by aggregation of a great variety of misfolded
proteins [91]. The most important of them are the Amyloid-
β (A-beta) peptides 1–40 and 1–42, derived from the β-
amyloid precursorprotein(APP).APPisdigestedbythepro-
teolytic enzymes beta-secretase and gama-secretase, which
producesAbeta40andAbeta42peptides.Thesemoleculesare
prone to form oligomers and to aggregate, producing neu-
rotoxic eﬀects upon neurons. The alternatively route of deg-
radation (nonamyloidogenic pathway) occurs via the α-
secretase, which cleaves within A-beta region and releases
soluble fragments including APP-α, a neurotrophic factor
par excelance [92].
Metabolism of APP is regulated by a great variety of
mechanisms, including the inﬂuence of certain growth fac-
tors, like insulin. In a cell culturemodel, itwas demonstrated
that insulin decreased intracellular and increase extracellular
concentrations of both A-beta40 and A-beta42 by stimulat-
ing intracellular traﬃcking [93]. Others, using diﬀerent cell
culture models, have showed that insulin deviates the APP
metabolism towardsthenonamyloidogenic, α-APP, pathway.
Conversely, with the increase on insulin resistance and its
decreased brain actions, occurs as an accumulation of A-beta
inside the cell, which could be one of the ﬁrst mechanisms
triggering neurodegeneration in Alzheimer’s disease [94].
Insulin-degrading enzyme (IDE) is an ubiquitously en-
zyme, which is highest expressed in liver, testes, muscle, and
brain. At the cellular level, it localizes primarily in the cyto-
plasmandperoxisomes.IDEisanotherpotentialexplanatory
link between insulin and Alzheimer’s disease. IDE degrades
insulin following its cell internalization, preventing the
accumulation of excessive intracellular insulin levels. Beside
insulin, IDE binds to a variety of other small peptides, like
insulin-likegrowthfactors1and2(IGF1and2),amylin, and
A-beta. These substrates have no homology in their primary
structure, although they share similar secondary structures
and an amyloidogenic characteristic [95, 96].
Theinterestintherelationship betweenDMandADgoes
beyond a possible cause-eﬀect of the ﬁrst upon the second.
In fact, abnormal amyloid metabolism seems to be a central
features in the pathophysiologies of both DM.2 and AD.
Amylin deposits in pancreatic islets cells are thought to have
a central feature in the pancreatic loss of Langerhans cells
associated withDM[97].Therefore,IDEactasa generalreg-
ulator of amyloid burden in both the pancreas and the brain.
Mutations in the IDE gene and environmental inﬂuences
which alter its expression might bring a common increased
risktodevelopbothDM.2andAD[96].Intheparticularcase
of β-amyloid plaque formation, IDE is the most important
A-beta scavenger protease, being liberated in extracellular
space and promoting A-beta cleavage [98].
The reaction catalyzed by IDE has diﬀerent Km depend-
ing on the substrate involved. Therefore, subtract competi-
tion for IDE degradation should be the rule. Insulin has a
lower Km(∼0,1mcM) when compared to A-beta(>2mcM),
what makes this molecule to be faster and preferentially
depredated by IDE. In fact, cells culture studies have found
that increased insulin concentration competes for IDE
degradation with A-beta, slowing its depuration rate [99].
IDE knockout animal models show accumulation of A-beta6 ISRN Neurology
peptides in the brain [95, 100], while APP mutant mice have
reduced plaque formation by increased expression of IDE
[101]. Therefore, in states of possible chronic brain high
insulin concentrations, A-beta can accumulate, oligomerize,
and formplaques,leading to a neurotoxicityand Alzheimer’s
disease.
Conversely,IDEcanbe inactivated by increased oxidative
stress, as it is often the case in obesity, and, specially,
metabolic syndrome [102, 103]. Brains of patients with both
Alzheimer’sdisease and MCIhavereducedexpression ofIDE
[104–106]. Furthermore, an allelic IDE gene variant seems
to correlate with both A-beta deposition and its plasmatic
levels [107, 108]. Therefore, IDE modulatory eﬀect in the
etiopathogeny of Alzheimer’s disease is already well estab-
lished. If IDE dysfunction and plaque formation are a cause
or a consequence of the rate of brain’s oxidative stress, aging,
and neurotoxicity is a question waiting for answer.
7.Insulinand Other GrowthFactors
In neuron-speciﬁc insulin receptorknockoutmice (NIRKO),
ultrastructural brain morphology and cognitive functions
seem to be absolutely normal, since they are not prone to
develop any kind of neurodegeneration. In fact, despite the
markedly reduced phosphorylation of Akt and GSK3-beta,
and the increased phosphorylation of tau,N I R K Om i c e
seems to pass through normal development and aging pro-
cesses [109]. This suggests that insulin resistance is not a
determinant of neurodegeneration, but rather a factor that
modiﬁes its risk and the rate of its process.
Insulin partakes the same signaling pathways with other
important general growth factors (IGF-1, BDNF, NGF, NT-
3, and GDNF) [29]. Taking into account the above data on
NIRKO mice, it is reasonable to consider the possibility of a
more general growthfactor resistance associated with insulin
resistance. According to this hypothesis, not only the loss of
the proper insulin activity can lead to neurodegeneration,
but also disturbances on other important neurotrophic fac-
tors, such as the above-mentioned ones. Absence of a well-
functioning web of neuroprotective mechanisms may turn
the activation of protective signals in response to stressors
ineﬃcient, increasing risk of neurodegeneration.
8.Conclusions
Almost all forms of neurodegenerative disorders are, early
or lately, associated with cognitive decline. Aging-related
cognitive dysfunction is a complex event which depends on
the net eﬀect of the interactions between many diﬀerent
mechanisms. Even though possibly not acting as primary
causative factors, insulin regulation and consequent glucose
homeostatic control are important concepts in providing a
uniﬁed hypothesis by which many age-related neurodegen-
erative diseases may be related. In fact, AD, PD, and PolyQ
disorders share in common the fact that all of them are
relatedtoproteinmisfolding,aggregation, and neurotoxicity.
Regardless of the speciﬁc genetic mechanisms involved,
environmental factors possibly play signiﬁcant roles in
fostering the precise neurodegenerative processes involvedin
these disorders. Moreover, a common pathway that regulates
the accumulation of misfolded proteins at a cellular level,
helping the internal cellular machinery to deal with these
neurotoxic aggregates could be a very plausible common
neuroprotective mechanism against these diseases.
Dysregulation in the glucose/insulin homeostatic control
is an extremely common condition in the modern word and
has long been related only with vascular diseases. Recently,
the association between insulin resistance and cognitive
decline/dementing processes such as AD have become evi-
dent. In fact, a great number of researchers worldwide are
currentlytrying to clarifytheexact roles ofinsulin regulation
and glycemic control upon the causative processes of AD
and other age-related neurodegenerative disease. Knowledge
of the speciﬁc mechanisms relating insulin dysregulation to
neurodegenerative diseases would probably allow the devel-
opment of drugs that may decelerate neurodegeneration.
Meanwhile, improvement of insulin sensitivity and reduc-
tion of peripheral hyperinsulinaemia through a healthy diet,
weight loss, and aerobic exercise may have beneﬁcial eﬀects
in preventing or delaying the progression of AD and other
neurodegenerative disorders.
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